NCT01175954View on ClinicalTrials.gov

Cognitive and Behavioral Effects of Lacosamide

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Epilepsy
Interventions
DRUG

Lacosamide

Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.

DRUG

Lacosamide

Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.

Trial Locations (1)

07601

Northeast Regional Epilepsy Group, Hackensack

Sponsors

Collaborators (1)

UCB Pharma
All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Evan Fertig

OTHER